Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece
暂无分享,去创建一个
G. Pentheroudakis | A. Batistatou | G. Zarkavelis | A. Papadaki | L. Kostadima | G. Nasioulas | D. Petrakis | E. Kampletsas | A. Papoudou-Bai | Vassiliki Metaxa-Mariatou | L. Mavroeidis | Angeliki Maria Lampraki | Ilias Tsinokou | Stefania Gκoura
[1] Massimo Cristofanilli,et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application , 2016, Oncotarget.
[2] J. Sicklick,et al. FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors , 2016, Journal of Translational Medicine.
[3] S. Ikeda,et al. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors. , 2016, JAMA oncology.
[4] C. Mancini,et al. Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors , 2016, Oncotarget.
[5] L. Shen,et al. Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors , 2016, Oncotarget.
[6] K. Søreide,et al. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. , 2016, Cancer epidemiology.
[7] J. Kopczyński,et al. Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases , 2016, Modern Pathology.
[8] H. Yao,et al. Clinicopathological significance of c-KIT mutation in gastrointestinal stromal tumors: a systematic review and meta-analysis , 2015, Scientific Reports.
[9] B. Druker,et al. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. , 2015, Cancer research.
[10] L. Borsu,et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing , 2015, Genes, chromosomes & cancer.
[11] J. Jónasson,et al. KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] I. Boukovinas,et al. Gastrointestinal Stromal Tumors (GIST): A Prospective Analysis and an Update on Biomarkers and Current Treatment Concepts , 2015, Biomarkers in cancer.
[13] J. Blay,et al. Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST , 2014, Clinical Cancer Research.
[14] C. Corless. Gastrointestinal stromal tumors: what do we know now? , 2014, Modern Pathology.
[15] M. Raffeld,et al. No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases , 2013, Modern Pathology.
[16] C. Antonescu,et al. Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants , 2013, PloS one.
[17] R. Kurzrock,et al. BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance , 2013, Oncotarget.
[18] A. Ballestrero,et al. Molecular characterization of an Italian series of sporadic GISTs , 2013, Gastric Cancer.
[19] J. Zalcberg,et al. Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors , 2012, Therapeutic advances in medical oncology.
[20] P. Sowa,et al. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] L. Mazzucchelli,et al. KRAS and BRAF Mutations Predict Primary Resistance to Imatinib in Gastrointestinal Stromal Tumors , 2012, Clinical Cancer Research.
[22] E. Zwarthoff,et al. Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST). , 2011, Cancer letters.
[23] J. Blay,et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours , 2010, Histopathology.
[24] J. Blay,et al. A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region , 2010, British Journal of Cancer.
[25] C. Ferreira,et al. Prognostic relevance of KIT and PDGFRA mutations in gastrointestinal stromal tumors. , 2010, Anticancer research.
[26] J. Lasota,et al. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. , 2009, Archives of pathology & laboratory medicine.
[27] R. Reis,et al. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild‐type GISTs , 2009, Histopathology.
[28] A. Hartmann,et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours , 2009, Journal of Clinical Pathology.
[29] L. Mazzucchelli,et al. Epidemiology and molecular biology of gastrointestinal stromal tumors (GISTs): a population-based study in the South of Switzerland, 1999-2005. , 2008, Histology and histopathology.
[30] Narasimhan P. Agaram,et al. Novel V600E BRAF mutations in imatinib‐naive and imatinib‐resistant gastrointestinal stromal tumors , 2008, Genes, chromosomes & cancer.
[31] C. Du,et al. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST) , 2008, Journal of surgical oncology.
[32] N. Pandis,et al. KIT exon 11 codon 557/558 deletion/insertion mutations define a subset of gastrointestinal stromal tumors with malignant potential. , 2008, World journal of gastroenterology.
[33] M. Heinrich,et al. Molecular pathobiology of gastrointestinal stromal sarcomas. , 2008, Annual review of pathology.
[34] J. Lasota,et al. Mutations in gastrointestinal stromal tumors – a population‐based study from Northern Norway , 2007, Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS).
[35] J. Blay,et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. , 2006, European journal of cancer.
[36] J. Lasota,et al. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). , 2006, Seminars in diagnostic pathology.
[37] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] E. Wardelmann,et al. Deletion of Trp‐557 and Lys‐558 in the juxtamembrane domain of the c‐kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors , 2003, International journal of cancer.
[39] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[40] L. Kindblom,et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.
[41] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[42] M. Mazur,et al. Gastric stromal tumors Reappraisal of histogenesis , 1983, The American journal of surgical pathology.
[43] P. G. Casali,et al. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] Jean-Yves Scoazec,et al. BRAF mutation status in gastrointestinal stromal tumors. , 2010, American journal of clinical pathology.